OmniAb, Inc.
Financials
Valuation Metrics
OmniAb, Inc.'s Market Cap is $737M. At end of 2025 it was $236M. Ranked #2575 of 3,118 in US market (top 83%), #1086 of 1,474 on NASDAQ (top 74%), #197 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $737M | US#2,575/3,118 Sec#197/265 |
| Revenue | $38M | US#2,755/3,118 Sec#151/265 |
| Net Income | $-44M | US—/3,118 Sec—/265 |
| Total Assets | $290M | US#2,907/3,118 Sec#209/265 |
| Net Assets | $260M | US#2,570/3,118 Sec#163/265 |
| Employees | 89 | US#2,637/3,118 Sec#184/265 |
| Value | ||
| P/B | 2.83x | US#1,711/3,118 Sec#92/265 |
| P/S | 19.18x | US#2,845/3,118 Sec#142/265 |
| FCF Yield | -2.46% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -17.01% | US#2,451/3,118 Sec#96/265 |
| ROA | -15.25% | US#2,740/3,118 Sec#120/265 |
| Op. Margin | -125.80% | US#2,720/3,118 Sec#126/265 |
| Revenue Growth | 66.89% | US#157/3,118 Sec#41/265 |
| Financial Health | ||
| Debt Ratio | 11.52% | US#125/3,118 Sec#55/265 |
| Total Debt | $19M | US#2,753/3,118 Sec#190/265 |
| FCF | $-18M | US#2,399/3,118 Sec#93/265 |
| Cash | $24M | US#2,805/3,118 Sec#250/265 |
| Current Ratio | 4.80x | US#491/3,118 Sec#146/265 |
| Performance | ||
| 1Y Return | 228.06% | US#25/3,118 Sec#11/265 |
| 1M Return | 4.41% | US#1,461/3,118 Sec#84/265 |
| From 52W High | -6.35% | US#489/3,118 Sec#34/265 |
| 1Y MDD | -37.04% | US#1,759/3,118 Sec#99/265 |
| Trading | ||
| Volume | 1,956,238 shares | US#904/3,118 Sec#81/265 |
| Trading Value | $10M | US#2,272/3,118 Sec#174/265 |
| Per Share | ||
| EPS | $-0.31 | US—/3,118 Sec—/265 |
| BPS | $1.80 | US#2,587/3,118 Sec#181/265 |
Company Info
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.